Wogonin ameliorates hyperglycemia and dyslipidemia via PPARα activation in db/db mice

Clinical Nutrition

Volumn 33, Issue 1, 2014, Pages 156-163

  Bak, Eun Jung ^a   Kim, Jinmoon ^a,b   Choi, Yun Hui ^a,b   Kim, Ji Hye ^a,b   Lee, Dong Eun ^a,b   Woo, Gye Hyeong ^c   Cha, Jeong Heon ^a,b   Yoo, Yun Jung ^a,b  

^a Yonsei University College of Dentistry   (South Korea)

^b Yonsei University   (South Korea)

^c Semyung University   (South Korea)

Author keywords

Hyperglycemia; Hyperlipidemia; Insulin; PPAR; Type 2 diabetes; Wogonin

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GLUCOSE; GLYCOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; WOGONIN;

ADIPOCYTE; ADIPOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; CELL DIFFERENTIATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; ENZYME ACTIVATION; FOOD INTAKE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HISTOPATHOLOGY; HYPERGLYCEMIA; IMMUNOBLOTTING; IN VITRO STUDY; INSULIN BLOOD LEVEL; LIPID STORAGE; LIVER LEVEL; MALE; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TOXICITY TESTING; TRANSACTIVATION; WEIGHT GAIN; WHITE ADIPOSE TISSUE;

HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN; PPAR; TYPE 2 DIABETES; WOGONIN;

3T3-L1 CELLS; ADIPOCYTES; ADIPONECTIN; ADIPOSE TISSUE, WHITE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CELL DIFFERENTIATION; CHOLESTEROL; DYSLIPIDEMIAS; FLAVANONES; GENE EXPRESSION; HYPERGLYCEMIA; INSULIN; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PPAR ALPHA; PPAR GAMMA;

EID: 84892552728     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2013.03.013     Document Type: Article

References (34)

1. Li S., Zhao J.H., Luan J., Langenberg C., Luben R.N., Khaw K.T., et al. Genetic predisposition to obesity leads to increased risk of type 2 diabetes. Diabetologia 2011, 54:776-782.
2. Stumvoll M., Goldstein B.J., van Haeften T.W. Pathogenesis of type 2 diabetes. Endocr Res 2007, 32:19-37.
3. Unger R.H., Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J 2001, 15:312-321.
4. Reaven G.M. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995, 75:473-486.
5. Cho M.C., Lee K., Paik S.G., Yoon D.Y. Peroxisome proliferators-activated receptor (PPAR) modulators and metabolic disorders. PPAR Res 2008, 2008:679137.
6. Hiukka A., Maranghi M., Matikainen N., Taskinen M.R. PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol 2010, 6:454-463.
7. Semple R.K., Chatterjee V.K., O'Rahilly S. PPAR gamma and human metabolic disease. JClin Invest 2006, 116:581-589.
8. Barish G.D., Narkar V.A., Evans R.M. PPAR delta: a dagger in the heart of the metabolic syndrome. JClin Invest 2006, 116:590-597.
9. Braissant O., Wahli W. Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology 1998, 139:2748-2754.
10. Kim H., Haluzik M., Asghar Z., Yau D., Joseph J.W., Fernandez A.M., et al. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 2003, 52:1770-1778.
11. Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994, 79:1147-1156.
12. Bateson M.C., Maclean D., Ross P.E., Bouchier I.A. Clofibrate therapy and gallstone induction. Am J Dig Dis 1978, 23:623-628.
13. Lebovitz H.E. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002, 18(Suppl. 2):S23-S29.
14. Colmers I.N., Bowker S.L., Johnson J.A. Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab 2012, 38:475-484.
15. Tai M.C., Tsang S.Y., Chang L.Y., Xue H. Therapeutic potential of wogonin: a naturally occurring flavonoid. CNS Drug Rev 2005, 11:141-150.
16. Jang S., Bak E.J., Kim M., Kim J.M., Chung W.Y., Cha J.H., et al. Wogonin inhibits osteoclast formation induced by lipopolysaccharide. Phytother Res 2010, 24:964-968.
17. Henkel J., Neuschafer-Rube F., Pathe-Neuschafer-Rube A., Puschel G.P. Aggravation by prostaglandin E2 of interleukin-6-dependent insulin resistance in hepatocytes. Hepatology 2009, 50:781-790.
18. 2 induced liver injury. Eur J Pharmacol 2006, 536:192-199.
19. Peng J., Qi Q., You Q., Hu R., Liu W., Feng F., et al. Subchronic toxicity and plasma pharmacokinetic studies on wogonin, a natural flavonoid, in Beagle dogs. JEthnopharmacol 2009, 124:257-262.
20. Student A.K., Hsu R.Y., Lane M.D. Induction of fatty acid synthetase synthesis in differentiating 3T3-L1 preadipocytes. JBiol Chem 1980, 255:4745-4750.
21. Kim J.B., Wright H.M., Wright M., Spiegelman B.M. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci U S A 1998, 95:4333-4337.
22. Takikawa M., Inoue S., Horio F., Tsuda T. Dietary anthocyanin-rich bilberry extract ameliorates hyperglycemia and insulin sensitivity via activation of AMP-activated protein kinase in diabetic mice. JNutr 2010, 140:527-533.
23. Chen C.Y., Shyue S.K., Ching L.C., Su K.H., Wu Y.L., Kou Y.R., et al. Wogonin promotes cholesterol efflux by increasing protein phosphatase 2B-dependent dephosphorylation at ATP-binding cassette transporter-A1 in macrophages. JNutr Biochem 2011, 22:1015-1021.
24. Ho F.M., Liao Y.H., Yang A.J., Lee Chao P.D., Hou Y.C., Huang C.T., et al. Anti-atherosclerotic action of Ger-Gen-Chyn-Lian-Tang and AMPK-dependent lipid lowering effect in hepatocytes. JEthnopharmacol 2012, 142:175-187.
25. DeFronzo R.A., Bonadonna R.C., Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992, 15:318-368.
26. Kim S., Shin H.J., Kim S.Y., Kim J.H., Lee Y.S., Kim D.H., et al. Genistein enhances expression of genes involved in fatty acid catabolism through activation of PPARalpha. Mol Cell Endocrinol 2004, 220:51-58.
27. Mulvihill E.E., Huff M.W. Protection from metabolic dysregulation, obesity, and atherosclerosis by citrus flavonoids: activation of hepatic PGC1alpha-mediated fatty acid oxidation. PPAR Res 2012, 2012. 857142.
28. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
29. Tsuchida A., Yamauchi T., Takekawa S., Hada Y., Ito Y., Maki T., et al. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 2005, 54:3358-3370.
30. Hiuge A., Tenenbaum A., Maeda N., Benderly M., Kumada M., Fisman E.Z., et al. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 2007, 27:635-641.
31. Lee Y.S., Kim W.S., Kim K.H., Yoon M.J., Cho H.J., Shen Y., et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55:2256-2264.
32. Saenz A., Fernandez-Esteban I., Mataix A., Ausejo M., Roque M., Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005, CD002966.
33. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., et al. Role of AMP-activated protein kinase in mechanism of metformin action. JClin Invest 2001, 108:1167-1174.
34. Huypens P., Quartier E., Pipeleers D., Van de Casteele M. Metformin reduces adiponectin protein expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase. Eur J Pharmacol 2005, 518:90-95.